Recombinant peptides in thrombolysis

Jennifer Campbell, Daniel E. Hilleman

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are alteplase (t-PA), reteplase (r-PA), and tenecteplase (TNK). r-PA and TNK have been structurally modified from native t-PA to increase their half-life and fibrin specificity. Thrombolytics play an important role in several diseases, including ST-segment elevation myocardial infarction (STEMI), deep vein thrombosis (DVT) and pulmonary embolism (PE), ischemic stroke, and peripheral arterial disease. Thrombolytic therapy has evolved into an alternative treatment for STEMI, reserved predominantly for patients who do not have access to timely percutaneous coronary intervention. In patients with DVT/PE or arterial related critical limb ischemia, the use of thrombolytic therapy is limited to specific patient populations. Thrombolytic therapy is the treatment of choice for ischemic stroke in patients who present 3 hours following the onset of symptoms. Moreover, thrombolytic therapy is used to restore function to stenotized central venous access devices as well as occluded hemodialysis access grafts.

Original languageEnglish
Pages (from-to)529-536
Number of pages8
JournalSeminars in Thrombosis and Hemostasis
Volume36
Issue number5
DOIs
StatePublished - 2010

Fingerprint

Thrombolytic Therapy
Tissue Plasminogen Activator
Peptides
Pulmonary Embolism
Venous Thrombosis
Stroke
Plasminogen
Peripheral Arterial Disease
Fibrinolysin
Percutaneous Coronary Intervention
Fibrin
Half-Life
Renal Dialysis
Peptide Hydrolases
Ischemia
Extremities
Transplants
Equipment and Supplies
Therapeutics
Population

All Science Journal Classification (ASJC) codes

  • Hematology
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Recombinant peptides in thrombolysis. / Campbell, Jennifer; Hilleman, Daniel E.

In: Seminars in Thrombosis and Hemostasis, Vol. 36, No. 5, 2010, p. 529-536.

Research output: Contribution to journalReview article

Campbell, Jennifer ; Hilleman, Daniel E. / Recombinant peptides in thrombolysis. In: Seminars in Thrombosis and Hemostasis. 2010 ; Vol. 36, No. 5. pp. 529-536.
@article{82d6a041d93e4b28804c565b94757a59,
title = "Recombinant peptides in thrombolysis",
abstract = "Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are alteplase (t-PA), reteplase (r-PA), and tenecteplase (TNK). r-PA and TNK have been structurally modified from native t-PA to increase their half-life and fibrin specificity. Thrombolytics play an important role in several diseases, including ST-segment elevation myocardial infarction (STEMI), deep vein thrombosis (DVT) and pulmonary embolism (PE), ischemic stroke, and peripheral arterial disease. Thrombolytic therapy has evolved into an alternative treatment for STEMI, reserved predominantly for patients who do not have access to timely percutaneous coronary intervention. In patients with DVT/PE or arterial related critical limb ischemia, the use of thrombolytic therapy is limited to specific patient populations. Thrombolytic therapy is the treatment of choice for ischemic stroke in patients who present 3 hours following the onset of symptoms. Moreover, thrombolytic therapy is used to restore function to stenotized central venous access devices as well as occluded hemodialysis access grafts.",
author = "Jennifer Campbell and Hilleman, {Daniel E.}",
year = "2010",
doi = "10.1055/s-0030-1255447",
language = "English",
volume = "36",
pages = "529--536",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "5",

}

TY - JOUR

T1 - Recombinant peptides in thrombolysis

AU - Campbell, Jennifer

AU - Hilleman, Daniel E.

PY - 2010

Y1 - 2010

N2 - Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are alteplase (t-PA), reteplase (r-PA), and tenecteplase (TNK). r-PA and TNK have been structurally modified from native t-PA to increase their half-life and fibrin specificity. Thrombolytics play an important role in several diseases, including ST-segment elevation myocardial infarction (STEMI), deep vein thrombosis (DVT) and pulmonary embolism (PE), ischemic stroke, and peripheral arterial disease. Thrombolytic therapy has evolved into an alternative treatment for STEMI, reserved predominantly for patients who do not have access to timely percutaneous coronary intervention. In patients with DVT/PE or arterial related critical limb ischemia, the use of thrombolytic therapy is limited to specific patient populations. Thrombolytic therapy is the treatment of choice for ischemic stroke in patients who present 3 hours following the onset of symptoms. Moreover, thrombolytic therapy is used to restore function to stenotized central venous access devices as well as occluded hemodialysis access grafts.

AB - Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are alteplase (t-PA), reteplase (r-PA), and tenecteplase (TNK). r-PA and TNK have been structurally modified from native t-PA to increase their half-life and fibrin specificity. Thrombolytics play an important role in several diseases, including ST-segment elevation myocardial infarction (STEMI), deep vein thrombosis (DVT) and pulmonary embolism (PE), ischemic stroke, and peripheral arterial disease. Thrombolytic therapy has evolved into an alternative treatment for STEMI, reserved predominantly for patients who do not have access to timely percutaneous coronary intervention. In patients with DVT/PE or arterial related critical limb ischemia, the use of thrombolytic therapy is limited to specific patient populations. Thrombolytic therapy is the treatment of choice for ischemic stroke in patients who present 3 hours following the onset of symptoms. Moreover, thrombolytic therapy is used to restore function to stenotized central venous access devices as well as occluded hemodialysis access grafts.

UR - http://www.scopus.com/inward/record.url?scp=77954876276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954876276&partnerID=8YFLogxK

U2 - 10.1055/s-0030-1255447

DO - 10.1055/s-0030-1255447

M3 - Review article

VL - 36

SP - 529

EP - 536

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 5

ER -